DAPA & AbbVie – Women’s Health Sessions – Session 2 – Thursday, June 24

DAPA & AbbVie – Women’s Health Sessions – Session 2 – Thursday, June 24

We're sorry, but all tickets sales have ended because the event is expired.
  • June 24, 2021
    6:00 pm - 7:00 pm

WEBINAR 2: Thursday, June 24 – 6PM CT

UTERINE FIBROIDS & Elagolix+Estradiol/NETA, indicated for heavy menstrual bleeding associated with uterine leiomyomas in pre-menopausal women

Uterine fibroids, also called leiomyomas, are estrogen and progesterone-dependent non-cancerous tumors of the uterus and are the most common type of benign tumor in women of reproductive age. Traditionally, uterine fibroids have been primarily managed by surgery and are the leading reason for the hysterectomies performed in the U.S. ORIAHNN (Elagolix+Estradiol/NETA) is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

This presentation will provide a brief scientific overview of disease state and clinical trial data for Elagolix+E2/NETA, indicated for heavy menstrual bleeding associated with fibroids (FDA approved May 2020). https://www.rxabbvie.com/pdf/oriahnn_pi.pdf

Women's Health_MSL_Maria Torres PhD